Holen Sie sich die Stockscreener-App
0.80
4.31%
-0.036
Handel nachbörslich:
.79
-0.01
-1.25%
Schlusskurs vom Vortag:
$0.836
Offen:
$0.8184
24-Stunden-Volumen:
108.84K
Relative Volume:
0.53
Marktkapitalisierung:
$48.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.67M
KGV:
-0.4103
EPS:
-1.95
Netto-Cashflow:
$-79.26M
1W Leistung:
-3.03%
1M Leistung:
-13.51%
6M Leistung:
-16.71%
1J Leistung:
-36.51%
1-Tages-Spanne:
$0.7899
$0.8499
1-Wochen-Bereich:
$0.7899
$0.8862
52-Wochen-Spanne:
$0.69
$1.60
Kronos Bio Inc Stock (KRON) Company Profile
Firmenname
Kronos Bio Inc
Sektor
Branche
Telefon
(650) 781-5200
Adresse
1300 S. EL CAMINO REAL, SAN MATEO
Vergleichen Sie KRON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRON
Kronos Bio Inc
|
0.80 | 48.78M | 0 | -112.67M | -79.26M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2022-09-14 | Eingeleitet | Berenberg | Buy |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-06-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Goldman | Buy |
| 2020-11-03 | Eingeleitet | Jefferies | Buy |
| 2020-11-03 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Kronos Bio Inc Aktie (KRON) Neueste Nachrichten
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
Kronos Bio Reports 2024 Financial Results - TipRanks
Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Kronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023) - Yahoo Finance
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Kronos Bio earnings missed by $0.17, revenue fell short of estimates - Investing.com Canada
Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com
Kronos Bio, Inc. SEC 10-K Report - TradingView
China Revives Its Carbon Credit Market: Price Swings & Future Outlook - The Globe and Mail
Navigating the U.S. Planting Season with Enhanced Risk Management - The Globe and Mail
Shootin' the Bull about cattle feeders - The Globe and Mail
KRONOS BIO Earnings Preview: Recent $KRON Insider Trading, Hedge Fund Activity, and More - Nasdaq
Kronos Bio (KRON) to Release Quarterly Earnings on Thursday - Defense World
Kronos Bio Insider Ups Holding By 36% During Year - Yahoo Finance
Kronos Bio, Inc. (NASDAQ:KRON) Shares Sold by Partners Capital Investment Group LLP - MarketBeat
Peapod Lane Capital LLC Purchases New Position in Kronos Bio, Inc. (NASDAQ:KRON) - MarketBeat
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up - MSN
Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Increases By 16.5% - MarketBeat
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully - Yahoo Finance
Analyzing Kronos Bio (NASDAQ:KRON) and Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Kronos Bio (NASDAQ:KRON) Stock Price Down 1.8% – Here’s What Happened - Defense World
Kronos Bio (NASDAQ:KRON) Stock Price Down 1.8%Should You Sell? - MarketBeat
Kronos Bio ends partnership with Genentech By Investing.com - Investing.com Australia
Kronos Bio ends partnership with Genentech - Investing.com India
Kronos Bio Ends Collaboration with Genentech and Roche - TipRanks
Kronos Bio (NASDAQ:KRON) Trading 8.5% HigherHere's Why - MarketBeat
Struggling Bay Area biotech firm Kronos, once worth $1B, lays off almost entire staff - SFGATE
Biotech with Cambridge lab slashes 83% of staff, CEO departs - NBC Boston
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - MSN
Finanzdaten der Kronos Bio Inc-Aktie (KRON)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):